Sartorius Stedim Biotech: Barclays raises its recommendation

(CercleFinance.com) - On Wednesday, Barclays raised its recommendation on Sartorius Stedim Biotech shares from 'weighted in line' to 'overweight', with a price target raised from €200 to €250.


In a note, the research firm hails the emergence of a 'new world' for the pharmaceutical and biopharmaceutical manufacturing industry, of which Sartorius Stedim Biotech is one of the two leading specialists in Europe along with its parent company Sartorius.

According to the analyst's calculations, the sector is only one quarter away from returning to the normal trajectory it would have followed without the emergence of Covid.

Despite this, both Sartorius Stedim Biotech and Sartorius are trading at much lower valuation levels than their peers, the analyst points out.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.